Nestle CEO defends packaged food ahead of Robert F. Kennedy Jr. confirmation
LONDON, Feb 13 (Reuters) - Packaged food provides safe, quality nutrition for people and reduces waste, Nestle's (NESN.S), opens new tab CEO said on Thursday, defending his company's products when asked how he would navigate incoming U.S. health secretary Robert F. Kennedy Jr.'s criticism of packaged food.
The U.S. Senate advanced President Donald Trump's nomination of Kennedy to head the Department of Health and Human Services on Wednesday, setting up a likely vote on awarding him the position in coming days.
If confirmed, as expected, by the Republican-controlled Senate, Kennedy, 71, would head the nation's top health agency that oversees agencies such as the Food and Drug Administration and the Centers for Disease Control and Prevention.
During his own presidential campaign, Kennedy said he wanted to "Make America Healthy Again" and called out Kellogg's Fruit Loops cereal in an interview in November.
Nestle is the world's biggest packaged foods group with products ranging from KitKat snacks and Nescafe coffee to Maggi noodles and Purina pet foods.
"The US is very, very important to us, and we are monitoring the situation," CEO Laurent Freixe said when asked if anyone at Nestle had spoken recently with Kennedy.
"Packaged foods are very, very important for mankind," he added. "They have brought safe foods to many. They preserve the quality of the food. They allow us to fight food waste."
Freixe, who was speaking after the company reported slightly better-than-forecast annual sales growth, said food insecurity and food-borne diseases would be more prevalent than they are today if not for packaged food.
He noted, however, that Nestle shared Kennedy's focus on nutrition and health.
"This is our goal as well. We are all for good diets, diverse diets and nutrient-rich diets," Freixe said.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 days ago
- NBC News
How RFK Jr. is quickly changing U.S. health agencies
WASHINGTON — In just a few short months, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to transform U.S. health policy: shrinking staff at health agencies, restructuring the focus of some regulators and researchers, changing Covid vaccine regulations and reshaping the mission of his department to focus more on alternative medicine. The directives are all part of the same issue set that drove a slice of health-conscious, left-leaning Americans to eventually vote for a Republican president whose favorite meal is from McDonald's, Trump and Kennedy catered to a type of voter who has grown distrustful of America's health care establishment — but possibly fomented a new type of distrust in federal health policy along the way. Bernadine Francis, a lifelong Democrat who backed Joe Biden for president in 2020 before supporting Donald Trump in 2024, told NBC News in an interview that she approves of Kennedy's efforts so far, despite his 'hands being tied' by entrenched forces in the administration and in Congress. 'From what I have seen so far with what RFK has been trying to do,' she said, 'I am really, really proud of what he's doing.' Francis is among the voters who left the Democratic Party and voted for Trump because 'nothing else mattered' apart from public health, which they — like Kennedy — felt was going in the wrong direction. Concerns about chemicals in food and toxins in the environment, long championed by Democrats, has become a galvanizing issue to a key portion of Trump's Republican Party, complete with an oversaturation of information that in some cases hasn't been proven. It's wrapped up, as well, in concerns about the Covid vaccine, which was accelerated under Trump, administered under Biden and weaponized by anti-vaccine activists like Kennedy amid lockdowns and firings in the wake of the devastating pandemic. 'We knew in order to get RFK in there so he can help with the situation that we have in the health industry, we knew we had to do this,' said Francis, a retired Washington, D.C., public school administrator, who said she left her 'beloved' career because she had refused the vaccine. 'It seemed to me, as soon as [Biden] became president, the vaccine was mandated, and that was when I lost all hope in the Democrats,' Francis told NBC News, referring to vaccination mandates put in place by the Biden administration for a large portion of the federal workforce during the height of the pandemic. There are not currently any federal Covid vaccine mandates. There have been 1,228,393 confirmed Covid deaths in the United States since the start of the pandemic, according to data from the Centers for Disease Control and Prevention. How RFK Jr.'s picks are changing public health agencies Dr. Marty Makary, Kennedy's hand-picked commissioner of the Food and Drug Administration and a John Hopkins scientist and researcher, told NBC News in an interview that he wants to transform the agency, which he said faced 'corruption' over influence from the pharmaceutical and food industries. 'I mean, you look at the food pyramid, it was not based on what's best for you, it was based on what companies wanted you to buy,' he said, referring to the 1992 and later iterations of official government nutritional guidance. He said there would be 'entirely new nutrition guidance' released later this year, as soon as this summer. He praised the FDA's mission of research and regulation, saying the agency is 'incredibly well-oiled, and we've got the trains running on time.' He also highlighted the 75-page 'Make America Healthy Again' commission report — which focused on ultraprocessed foods and toxins in the environment — as having set 'the agenda for research' at the FDA, HHS and agencies overseeing social safety net programs such as Medicare and food stamps moving forward. (The MAHA report initially cited some studies that didn't exist, a mistake that Kennedy adviser Calley Means said was a 'great disservice' to their mission.) 'I think there's a lot we're going to learn. For example, the microbiome, which gets attention in the MAHA report, needs to be on the map. We don't even talk about it in our medical circles,' Makary said. 'The microbiome, food is medicine, the immune response that happens when chemicals that don't appear in nature go down our GI tract.' Pressed on other areas of the administration, like the Environmental Protection Agency, making decisions that run counter to the pro-regulatory ideas presented in the MAHA report, Makary said he can 'only comment on the FDA' where they are 'committed to Secretary Kennedy's vision.' But Kennedy's public health agenda goes beyond looking at the food supply and chemicals. Recently, Kennedy said in a video posted on X last month that the Covid vaccine is no longer recommended for healthy children and pregnant women, a change in CDC guidance that skipped the normal public review period. Days later, after critics questioned the decision and raised concerns over a lack of public data behind the move, the administration updated its guidance again, urging parents to consult with their doctors instead. Pressed about the confusion and whether Americans are now trading one side of public distrust in the health system for another, Makary defended Kennedy, who has been criticized for spreading misinformation. 'My experience with Secretary Robert F. Kennedy is that he listens. He listens to myself, he listens to Jay Bhattacharya, listens to Dr. Mehmet Oz, he listens to a host of scientists that are giving him guidance,' Makary argued, referring to the director of the National Institutes of Health and the administrator for the Centers for Medicare & Medicaid Services, respectively. 'So he may have big questions, but the questions he's asking are the questions most Americans are asking.' The intersection of medicine and healthy lifestyle choices Dr. Dawn Mussallem, a breast cancer oncologist and integrative medicine doctor — a physician who combines conventional treatments with research-based alternative therapies — has tried to help her patients wade through medical misinformation they encounter online and in their social circles. Mussallem has an incredible story of personal survival: While in medical school, she was diagnosed with Stage IV cancer and, after conventional therapies like chemo saved her life, was diagnosed with heart failure. After undergoing a heart transplant, Mussallem ran a 26-mile marathon just one year later. 'I learned a lot in medical school, but nothing compared to what I learned being a patient,' said Mussallem, who dedicates, on average, 90 minutes each in one-on-one sessions with her patients. 'This is not about any one political choice. But we know lifestyle matters.' For example, a new study from the American Society of Clinical Oncology that finds eating food that lowers inflammation in the body may help people with advanced colon cancer survive longer. Mussallem's mission, along with her colleagues, is to elevate the modern medicine that saved her life, as well as encouraging her patients to live healthy lifestyles, including regular exercise, minimally processed foods, less screen time, more social connection and better sleep. But politics do get in the way for millions of Americans who are inundated daily with social media influencers and 'nonmedical experts,' as Mussallem puts it, who stoke fear in her patients. 'Patients come in with all these questions, fears,' she said. 'I've heard this many times from patients, that their nervous system is affected by what they're seeing happening in government.' Mussallem acknowledges that 'a lot of individuals out there' have questioned traditional medicine. For her, it isn't one or the other — it's both. 'We have to trust the conventional medicine,' she said. 'With the conventional care that marches right alongside more of an integrative modality to look at the root causes of disease, as well as to help to optimize with lifestyle, is where we need to be.'
Reuters
3 days ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
3 days ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
